Dasatinib 50mg Tablet

Dasatinib 50mg Tablet contains dasatinib 50mg, an oral prescription tyrosine kinase inhibitor (TKI) used in the treatment of certain Philadelphia chromosome-positive (Ph+) leukemias, including chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dasatinib inhibits abnormal BCR-ABL signaling and other kinases involved in leukemia-cell proliferation.

Sprycel® is the reference brand containing dasatinib. Dasatinib 50mg is an established tablet strength and is available in generic products in certain markets. Treatment should be prescribed and monitored by a healthcare professional experienced in leukemia management.

Product Information

Generic Name

Dasatinib

Active Ingredient

Dasatinib

Strength

50mg

Dosage Form

Film-Coated Tablet

Drug Class

Tyrosine Kinase Inhibitor (TKI)

Target

BCR-ABL, SRC-family kinases and other tyrosine kinases

Therapeutic Class

Targeted Anticancer Therapy

Reference Brand

Sprycel®

Reference Manufacturer

Bristol Myers Squibb

Route

Oral

Primary Uses

Philadelphia chromosome-positive CML and Ph+ ALL

Prescription

Yes

Tablet Strengths

20mg, 50mg, 70mg, 80mg, 100mg and 140mg depending on market

Pack Size

Manufacturer and market dependent

Administration

Once daily regimens are used for several approved indications; dosage depends on disease type and treatment setting.

What Is Dasatinib 50mg Tablet?

Dasatinib is a targeted oral anticancer medicine belonging to the BCR-ABL tyrosine kinase inhibitor class.

It is designed to inhibit abnormal kinase proteins that contribute to the development and progression of certain leukemias. Dasatinib is particularly important in Philadelphia chromosome-positive disease, where the BCR-ABL fusion protein produces abnormal kinase activity that promotes uncontrolled leukemia-cell growth.

Dasatinib 50mg for CML

Chronic myeloid leukemia is a blood cancer characterized in many patients by the presence of the Philadelphia chromosome and BCR-ABL fusion gene.

Dasatinib provides targeted inhibition of BCR-ABL and is used as an important treatment option for Ph+ CML.

For newly diagnosed adult chronic-phase CML, the standard starting dose of dasatinib in the current European product information is 100mg once daily, meaning the 50mg tablet strength may be used as part of dose adjustment or according to an individualized treatment plan rather than necessarily representing the standard starting dose.

Dasatinib 50mg for Ph+ ALL

Dasatinib is also used for Philadelphia chromosome-positive acute lymphoblastic leukemia in approved treatment settings.

Ph+ ALL contains the BCR-ABL abnormality, making BCR-ABL inhibition an important component of targeted treatment.

In adult Ph+ ALL and lymphoid blast-phase CML, the recommended starting dose in the European product information is 140mg once daily, with treatment adjustments made according to clinical response and tolerability.

Dasatinib 50mg and Sprycel®

Sprycel® contains dasatinib and is the reference brand.

Dasatinib 50mg is therefore commonly searched alongside:

Dasatinib 50mg, Generic Dasatinib 50mg, Generic Sprycel 50mg, Sprycel 50mg, Dasatinib 50mg Tablet, Dasatinib Alternative, Sprycel Alternative, BCR-ABL Inhibitor and CML Treatment.

Authorized generic dasatinib products are available in some markets. The European Medicines Agency has authorized generic dasatinib products containing the same active substance as the reference medicine Sprycel.

Dasatinib 50mg Monitoring

Treatment with dasatinib generally requires regular clinical and laboratory monitoring.

Healthcare professionals may monitor:

• Complete blood count
• Platelet count
• Hemoglobin
• Neutrophil count
• Liver function
• Renal function where appropriate
• Signs of bleeding
• Fluid retention
• Respiratory symptoms
• Cardiovascular status
• Leukemia response and molecular markers

Dose interruptions or reductions may be required when significant adverse reactions or abnormal blood counts occur.

Availability & Ordering

Dasatinib 50mg Tablet is a prescription oncology medicine supplied for patients with an appropriate leukemia diagnosis and treatment plan.

Commercial searches include Dasatinib 50mg Tablet, Dasatinib 50mg, Generic Dasatinib 50mg, Generic Sprycel 50mg, Sprycel 50mg, Buy Dasatinib 50mg, Buy Dasatinib Online, Dasatinib 50mg Price, Dasatinib Supplier, Dasatinib 50mg Capsules/Tablets, CML Medicine, BCR-ABL Inhibitor and Leukemia Treatment.

Dasatinib should be obtained through an appropriately licensed pharmacy or authorized pharmaceutical supplier. Availability, prescription requirements, approved indications and import regulations differ across the USA, UK, UAE/Dubai, Australia, Singapore, Thailand, China and Russia.

How it works

Dasatinib blocks several tyrosine kinases, most importantly BCR-ABL, which is produced by the Philadelphia chromosome abnormality found in many patients with CML and some patients with ALL.

By inhibiting BCR-ABL signaling, dasatinib interferes with pathways that promote leukemia-cell survival and proliferation.

Dasatinib also inhibits SRC-family kinases and other kinase targets, contributing to its broader targeted activity.

Dasatinib is used for eligible patients with:

• Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)
• Newly diagnosed Ph+ CML in chronic phase
• Chronic, accelerated or blast-phase CML when there is resistance or intolerance to previous therapy including imatinib
• Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in specified treatment settings
• Lymphoid blast-phase CML in applicable treatment settings

Pediatric indications are also approved in certain regulatory markets and depend on age, disease status and treatment regimen.

Dasatinib dosage varies substantially according to:

• Type of leukemia
• Disease phase
• Previous treatment
• Patient age
• Response to therapy
• Blood-cell counts
• Adverse reactions
• Drug interactions

For adults, regulatory product information lists different starting doses for chronic-phase CML versus advanced-phase CML and Ph+ ALL. Therefore, 50mg should not be assumed to be the standard dose for every patient.

Take dasatinib exactly as prescribed by the treating oncologist. Do not alter the dose, frequency or treatment schedule without medical advice.

Dasatinib can cause adverse reactions and requires specialist monitoring.

Common or clinically important adverse effects may include:

• Thrombocytopenia
• Neutropenia
• Anemia
• Diarrhea
• Nausea
• Headache
• Fatigue
• Rash
• Musculoskeletal pain
• Fluid retention
• Peripheral edema
• Pleural effusion

More serious complications can occur, including significant blood-count abnormalities, pleural or pulmonary complications, pulmonary arterial hypertension and other cardiovascular or bleeding-related events.

Patients should promptly report breathing difficulties, chest discomfort, unusual bleeding, severe weakness or other concerning symptoms to their healthcare provider.

Dasatinib has clinically important drug interactions.

Medicines that affect CYP3A4 can alter dasatinib exposure. Acid-reducing medicines may also affect absorption depending on the specific formulation and prescribing information.

Patients should tell their oncologist or pharmacist about all prescription medicines, over-the-counter products, vitamins and herbal supplements before starting treatment.